LeMaitre Vascular Inc
NASDAQ:LMAT

Watchlist Manager
LeMaitre Vascular Inc Logo
LeMaitre Vascular Inc
NASDAQ:LMAT
Watchlist
Price: 106.62 USD -3.36% Market Closed
Market Cap: $2.4B

LeMaitre Vascular Inc
Investor Relations

LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency.

The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Feb 25, 2026
AI Summary
Q4 2025

Strong Growth: LeMaitre delivered 16% sales growth in Q4 and 14% for full-year 2025, with broad-based performance across products and geographies.

Margin Expansion: Gross margin improved to 71.7% in Q4 (up 240 bps YoY) and operating income rose 47% to $18.8 million, with operating margin at 29%.

International Strength: EMEA sales grew 29% in Q4, APAC 20%, and Americas 10%; Artegraft’s OUS performance beat expectations, contributing to a raised TAM estimate.

2026 Guidance: Management expects 12% revenue growth to $280 million, gross margin of 72.1%, and EPS of $2.91 (up 22%), with $77.8 million in operating income (up 21%).

Price Increases: A blended 8% price hike was implemented in January, with smooth transitions and positive acceptance in both the US and Europe.

Capital Allocation: Announced $100 million share repurchase program and a 25% higher Q1 2026 dividend ($0.25/share), marking 15 consecutive years of dividend increases.

M&A Optionality: With $359 million in cash and securities, the company remains focused on disciplined, targeted acquisitions but continues to demonstrate strong organic growth.

Cyber Incident Contained: A January 2026 cyber incident had minimal operational impact and is reflected in 2026 guidance.

Key Financials
Revenue
$280 million
Revenue
$1.9 million (International sales, Q4 2025)
Revenue
$4 million (International Artegraft, FY 2025)
Gross Margin
71.7%
Operating Income
$18.8 million (Q4 2025)
Operating Margin
29% (Q4 2025)
EPS
$0.68 (Q4 2025)
EPS
$2.91 (2026 guidance)
Adjusted Gross Margin
70.4% (FY 2025)
Adjusted Operating Margin
26% (FY 2025)
Free Cash Flow
$74.5 million (FY 2025)
Cash and Securities
$359 million (end of 2025)
Operating Cash Flow
$23.1 million (Q4 2025)
CapEx
$1.8 million (Q4 2025)
Free Cash Flow
$21.3 million (Q4 2025)
Dividend per Share
$0.25 (Q1 2026)
Sales Rep Headcount
160 (end of 2025)
Tax Rate
23.2% (Q4 and FY 2025)
Earnings Call Recording
Other Earnings Calls

Management

Mr. George W. LeMaitre
Chairman & CEO
No Bio Available
Mr. David B. Roberts
President & Director
No Bio Available
Mr. Joseph P. Pellegrino Jr.
CFO, Secretary & Director
No Bio Available
Mr. Trent G. Kamke
Senior Vice President of Operations
No Bio Available
Dr. George D. LeMaitre
Founder and Chairman of Scientific Advisory Board
No Bio Available
Ms. Kimberly L. Cieslak
Vice President of Marketing
No Bio Available
Mr. Daniel J. Mumford
Senior Director of Human Resources
No Bio Available
Mr. Jonathan W. Ngau
Senior Vice President of Information Technology
No Bio Available
Mr. Maik D. Helmers
Senior Vice President of Sales ? Central Europe
No Bio Available
Mr. Ryan H. Connelly
Senior Vice President of Advanced Manufacturing Engineering
No Bio Available

Contacts

Address
MASSACHUSETTS
Burlington
63 2nd Ave
Contacts
+17812212266.0
www.lemaitre.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett